JP2018078911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018078911A5 JP2018078911A5 JP2018017340A JP2018017340A JP2018078911A5 JP 2018078911 A5 JP2018078911 A5 JP 2018078911A5 JP 2018017340 A JP2018017340 A JP 2018017340A JP 2018017340 A JP2018017340 A JP 2018017340A JP 2018078911 A5 JP2018078911 A5 JP 2018078911A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- inhibitors
- inhibitor
- amplification
- copy number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039189 Transcription factor Maf Human genes 0.000 claims 62
- 239000003112 inhibitor Substances 0.000 claims 32
- 230000003321 amplification Effects 0.000 claims 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims 27
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- 206010027476 Metastases Diseases 0.000 claims 19
- 102000014128 RANK Ligand Human genes 0.000 claims 18
- 108010025832 RANK Ligand Proteins 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 18
- 206010060862 Prostate cancer Diseases 0.000 claims 17
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 17
- 210000000988 bone and bone Anatomy 0.000 claims 16
- 230000009401 metastasis Effects 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 230000005945 translocation Effects 0.000 claims 12
- 239000013068 control sample Substances 0.000 claims 11
- 230000015556 catabolic process Effects 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 238000006731 degradation reaction Methods 0.000 claims 10
- 229940122361 Bisphosphonate Drugs 0.000 claims 9
- 108020004635 Complementary DNA Proteins 0.000 claims 9
- 150000004663 bisphosphonates Chemical class 0.000 claims 9
- 238000010804 cDNA synthesis Methods 0.000 claims 9
- 239000002299 complementary DNA Substances 0.000 claims 9
- 108020004999 messenger RNA Proteins 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 206010027452 Metastases to bone Diseases 0.000 claims 7
- 238000011002 quantification Methods 0.000 claims 7
- 102000055006 Calcitonin Human genes 0.000 claims 6
- 108060001064 Calcitonin Proteins 0.000 claims 6
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims 6
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 6
- 108090000445 Parathyroid hormone Proteins 0.000 claims 6
- 102100036893 Parathyroid hormone Human genes 0.000 claims 6
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims 6
- 102000001332 SRC Human genes 0.000 claims 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 6
- 229960004015 calcitonin Drugs 0.000 claims 6
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 6
- 229940111134 coxibs Drugs 0.000 claims 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 229940043355 kinase inhibitor Drugs 0.000 claims 6
- 229940124302 mTOR inhibitor Drugs 0.000 claims 6
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 6
- 108010087686 src-Family Kinases Proteins 0.000 claims 6
- 229940079488 strontium ranelate Drugs 0.000 claims 6
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims 6
- 229940097000 DKK-1 inhibitor Drugs 0.000 claims 5
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims 5
- 229940125436 dual inhibitor Drugs 0.000 claims 5
- 239000002834 estrogen receptor modulator Substances 0.000 claims 5
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims 4
- 229960005562 radium-223 Drugs 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 3
- 102000008108 Osteoprotegerin Human genes 0.000 claims 3
- 108010035042 Osteoprotegerin Proteins 0.000 claims 3
- 238000003491 array Methods 0.000 claims 3
- 229960001251 denosumab Drugs 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- 238000007901 in situ hybridization Methods 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 3
- 230000000010 osteolytic effect Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000003498 protein array Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 238000003753 real-time PCR Methods 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 238000001262 western blot Methods 0.000 claims 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 3
- 229960004276 zoledronic acid Drugs 0.000 claims 3
- 102000004171 Cathepsin K Human genes 0.000 claims 2
- 108090000625 Cathepsin K Proteins 0.000 claims 2
- 230000004544 DNA amplification Effects 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims 1
- -1 EGFR inhibitors Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713318P | 2012-10-12 | 2012-10-12 | |
| US61/713,318 | 2012-10-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016048499A Division JP6446381B2 (ja) | 2012-10-12 | 2016-03-11 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018078911A JP2018078911A (ja) | 2018-05-24 |
| JP2018078911A5 true JP2018078911A5 (OSRAM) | 2019-01-17 |
| JP6636067B2 JP6636067B2 (ja) | 2020-01-29 |
Family
ID=49998595
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536237A Active JP6074049B2 (ja) | 2012-10-12 | 2013-10-09 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| JP2016048499A Active JP6446381B2 (ja) | 2012-10-12 | 2016-03-11 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| JP2018017340A Active JP6636067B2 (ja) | 2012-10-12 | 2018-02-02 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536237A Active JP6074049B2 (ja) | 2012-10-12 | 2013-10-09 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| JP2016048499A Active JP6446381B2 (ja) | 2012-10-12 | 2016-03-11 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140105918A1 (OSRAM) |
| EP (2) | EP2906718B1 (OSRAM) |
| JP (3) | JP6074049B2 (OSRAM) |
| KR (1) | KR101872965B1 (OSRAM) |
| CN (1) | CN104995313A (OSRAM) |
| AU (1) | AU2016213773B2 (OSRAM) |
| BR (1) | BR112015008255B1 (OSRAM) |
| CA (1) | CA2888122A1 (OSRAM) |
| DK (1) | DK2906718T3 (OSRAM) |
| ES (2) | ES2906586T3 (OSRAM) |
| HK (1) | HK1213946A1 (OSRAM) |
| MX (1) | MX365421B (OSRAM) |
| WO (1) | WO2014057357A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| US11206976B2 (en) * | 2014-10-16 | 2021-12-28 | New York University | Method and system for simultaneous decomposition of multiple hyperspectral datasets and signal recovery of unknown fluorophores in a biochemical system |
| CA2967224C (en) * | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| US20180303830A1 (en) * | 2015-06-22 | 2018-10-25 | Thomas Jefferson University | Cancers expressing ccr5 and methods of treatment of same |
| DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| CZ307369B6 (cs) * | 2016-12-22 | 2018-07-04 | České vysoké učení technické v Praze | Kombinace pro radionuklidovou terapii pro použití jako léčivo |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| TW202012637A (zh) * | 2018-04-24 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2024130224A2 (en) * | 2022-12-16 | 2024-06-20 | Purdue Research Foundation | Stapled peptides for sensitization of cancer to treatment |
| CN116287250B (zh) * | 2023-01-18 | 2025-12-16 | 中山大学附属第七医院(深圳) | 一种前列腺癌骨转移诊断、治疗和/或预后的标志物及其应用 |
| CN119007946B (zh) * | 2024-08-02 | 2025-02-07 | 连云港市第二人民医院(连云港市临床肿瘤研究所) | 一种用于肿瘤患者的全病程智能化医疗管理系统 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3688418T2 (de) | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| DE951551T1 (de) | 1996-12-23 | 2000-09-14 | Immunex Corp., Seattle | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| HK1039108A1 (zh) | 1999-03-15 | 2002-04-12 | Axys Pharmaceuticals, Inc. | 以n-氰甲基酰胺作为蛋白酶抑制剂 |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| JP2003525874A (ja) | 2000-01-06 | 2003-09-02 | メルク フロスト カナダ アンド カンパニー | プロテアーゼ阻害剤としての新規化合物および組成物 |
| EP1256344B1 (en) | 2000-02-16 | 2006-12-20 | Astellas Pharma Inc. | Remedies for endothelin-induced diseases |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| JP4579581B2 (ja) | 2003-12-08 | 2010-11-10 | 株式会社グリーンペプタイド | 副甲状腺ホルモン関連タンパク質のｈｌａ−ａ２４またはｈｌａ−ａ２結合ペプチド |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1706137A2 (en) * | 2004-01-21 | 2006-10-04 | Chiron Corporation | M-csf muteins and uses thereof |
| EP1767541A4 (en) | 2004-05-26 | 2008-10-22 | Greenpeptide Co Ltd | HLA-A24 OR HLA-A2 BINDING PEPTIDE OF THE PARATHYROID HORMONE-RELATED PROTEIN |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP1941050B1 (en) | 2005-09-20 | 2017-04-26 | Janssen Diagnostics, LLC | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| CA2632451C (en) | 2005-12-06 | 2015-11-03 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US8080384B2 (en) * | 2006-04-05 | 2011-12-20 | Yokohama City University | Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| CA2702805A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| CN102123708A (zh) | 2008-06-06 | 2011-07-13 | 大学健康网络 | 用于治疗恶性血液疾病的8-羟基喹啉衍生物 |
| AR075613A1 (es) | 2009-02-25 | 2011-04-20 | Merrion Res Iii Ltd | Composicion y suministro de drogas de bifosfonato. metodo de tratamiento |
| ES2379918B1 (es) * | 2010-10-06 | 2013-05-10 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama. |
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| EP2678448A4 (en) | 2011-02-22 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20140105918A1 (en) * | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014140896A2 (es) | 2013-03-15 | 2014-09-18 | Fundacio Privada Institut De Recerca Biomedica | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| MX362041B (es) | 2013-10-09 | 2019-01-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| DK3158057T3 (da) | 2014-06-17 | 2019-07-29 | Igenomix S L | Stamcelleterapi ved endometriepatologier |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
-
2013
- 2013-10-09 US US14/050,262 patent/US20140105918A1/en not_active Abandoned
- 2013-10-09 ES ES19174485T patent/ES2906586T3/es active Active
- 2013-10-09 CA CA2888122A patent/CA2888122A1/en not_active Abandoned
- 2013-10-09 BR BR112015008255-6A patent/BR112015008255B1/pt active IP Right Grant
- 2013-10-09 MX MX2015004610A patent/MX365421B/es active IP Right Grant
- 2013-10-09 CN CN201380060218.XA patent/CN104995313A/zh active Pending
- 2013-10-09 JP JP2015536237A patent/JP6074049B2/ja active Active
- 2013-10-09 KR KR1020157012297A patent/KR101872965B1/ko active Active
- 2013-10-09 DK DK13821939.9T patent/DK2906718T3/da active
- 2013-10-09 EP EP13821939.9A patent/EP2906718B1/en active Active
- 2013-10-09 HK HK16101721.6A patent/HK1213946A1/zh unknown
- 2013-10-09 US US14/435,128 patent/US10114022B2/en active Active
- 2013-10-09 EP EP19174485.3A patent/EP3553186B1/en active Active
- 2013-10-09 WO PCT/IB2013/002866 patent/WO2014057357A2/en not_active Ceased
- 2013-10-09 ES ES13821939T patent/ES2744244T3/es active Active
-
2016
- 2016-03-11 JP JP2016048499A patent/JP6446381B2/ja active Active
- 2016-08-10 AU AU2016213773A patent/AU2016213773B2/en active Active
-
2018
- 2018-02-02 JP JP2018017340A patent/JP6636067B2/ja active Active
- 2018-09-18 US US16/134,449 patent/US11041861B2/en active Active
-
2021
- 2021-06-04 US US17/339,024 patent/US11892453B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018078911A5 (OSRAM) | ||
| JP2016105731A5 (OSRAM) | ||
| JP2016516403A5 (OSRAM) | ||
| JP2022125079A (ja) | がん転移の予後診断および処置のための方法 | |
| JP6430560B2 (ja) | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ | |
| JP2016539625A5 (OSRAM) | ||
| CN103834729B (zh) | 肺癌的多基因预后试验 | |
| KR102226219B1 (ko) | 폐암 전이의 진단, 예후 및 치료 방법 | |
| EP1917528B1 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators | |
| CN108192972B (zh) | 用于乳腺癌转移的诊断、预后和治疗的方法 | |
| AU2014333513B2 (en) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer | |
| JP2013541339A5 (OSRAM) | ||
| JP2015521050A5 (OSRAM) | ||
| JP2019523641A5 (OSRAM) | ||
| KR20150122731A (ko) | 암 전이의 예후 및 치료 방법 | |
| EP3140427A2 (en) | Biomarkers for response to pi3k inhibitors | |
| CN104995313A (zh) | 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法 | |
| CN106661624B (zh) | 用于癌症诊断、预后和治疗选择的着丝粒/动粒蛋白基因 | |
| US20100292303A1 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
| JP2012522756A5 (OSRAM) | ||
| Zhang et al. | Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer | |
| JP2008512984A5 (OSRAM) | ||
| JP5918694B2 (ja) | 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ | |
| Pio et al. | Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer | |
| JP7503864B2 (ja) | 免疫抗がん療法に対するバイオマーカーおよびその用途 |